StockData
Pulmonx Corp logo

Pulmonx Corp (LUNG) stock

LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3044% below fair value
$2.69−0.04 (-1.65%)

Close on Nov 18, 2026Market cap $115.53MP/E –Yield –

Pulmonx free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Pulmonx's free cash flow for the twelve months ending Jun 30, 2026 was -$30.67M. For fiscal 2025 it was -$32.83M. The highest annual figure on record is -$18.71M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$32.83M–
FY2024Dec 31, 2024-$32.98M–
FY2023Dec 31, 2023-$38.42M–
FY2022Dec 31, 2022-$46.40M–
FY2021Dec 31, 2021-$45.06M–
FY2020Dec 31, 2020-$31.54M–
FY2019Dec 31, 2019-$21.49M–
FY2018Dec 31, 2018-$18.71M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.22M–
Q1 FY2026Mar 31, 2026-$10.11M–
Q4 FY2025Dec 31, 2025-$7.10M–
Q3 FY2025Sep 30, 2025-$8.25M–
Q2 FY2025Jun 30, 2025-$3.96M–
Q1 FY2025Mar 31, 2025-$13.52M–
Q4 FY2024Dec 31, 2024-$6.84M–
Q3 FY2024Sep 30, 2024-$7.66M–
Q2 FY2024Jun 30, 2024-$6.24M–
Q1 FY2024Mar 31, 2024-$12.25M–
Q4 FY2023Dec 31, 2023-$8.65M–
Q3 FY2023Sep 30, 2023-$9.12M–
Q2 FY2023Jun 30, 2023-$7.95M–
Q1 FY2023Mar 31, 2023-$12.71M–
Q4 FY2022Dec 31, 2022-$9.98M–
Q3 FY2022Sep 30, 2022-$10.97M–
Q2 FY2022Jun 30, 2022-$9.86M–
Q1 FY2022Mar 31, 2022-$15.59M–
Q4 FY2021Dec 31, 2021-$11.86M–
Q3 FY2021Sep 30, 2021-$9.94M–
Q2 FY2021Jun 30, 2021-$13.35M–
Q1 FY2021Mar 31, 2021-$9.91M–
Q4 FY2020Dec 31, 2020-$7.96M–
Q3 FY2020Sep 30, 2020-$5.91M–
Q2 FY2020Jun 30, 2020-$7.75M–
Q1 FY2020Mar 31, 2020-$9.93M–
Q4 FY2019Dec 31, 2019-$3.69M–

More Pulmonx figures

See a number that looks wrong?